This manual guides physicians in the use of medications to help patients achieve abstinence from alcohol. It describes how the medications work, whom they benefit, and side effects for three FDA-approved medications: acamprosate, disulfiram, and naltrexone.
You May Also Be Interested In
Advisory: Prescribing Pharmacotherapies for Patients With Alcohol Use Disorder
This Advisory, based on TIP 49, Incorporating Alcohol Pharmacotherapies Into Medical Practice, focuses on medication and related treatment decisions made after screening and assessment for AUD, and medically supervised withdrawal, if necessary. Alcohol consumption should not stop abruptly in those patients who have consumed alcohol regularly over a prolonged period of time. This Advisory is meant as an overview of AUD medications to facilitate abstinence.
TIP 48: Managing Depressive Symptoms in Substance Abuse Clients During Early Recovery
This guide helps substance use counselors treat clients with symptoms of depression and substance use conditions. Program administrators will learn how to integrate depression treatment into early drug treatment. The guidelines cover screening, assessment, treatment, counseling, cultural competence, and continuing care.
TIP 49: Incorporating Alcohol Pharmacotherapies Into Medical Practice
This manual provides clinical practice guidelines for using medications in the medication-assisted treatment of alcohol use disorder. It offers guidance on prescribing acamprosate, disulfiram, oral naltrexone, and extended-release injectable naltrexone. The manual also discusses patient management. Access the literature review.